

Munc18-1 Is Essential for Neuropeptide Secretion in Neurons

 Daniël C. Puntman,¹  Swati Arora,² Margherita Farina,¹  Ruud F. Toonen,² and Matthijs Verhage^{1,2}

¹Section Functional genomics, Department of Clinical Genetics, Center for Neurogenomics and Cognitive Research, Universitair Medisch Centrum, Amsterdam 1081 HV, The Netherlands, and ²Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands

Neuropeptide secretion from dense-core vesicles (DCVs) controls many brain functions. Several components of the DCV exocytosis machinery have recently been identified, but the participation of a SEC1/MUNC18 (SM) protein has remained elusive. Here, we tested the ability of the three exocytic SM proteins expressed in the mammalian brain, MUNC18-1/2/3, to support neuropeptide secretion. We quantified DCV exocytosis at a single vesicle resolution on action potential (AP) train-stimulation in mouse CNS neurons (of unknown sex) using pHluorin-tagged and/or mCherry-tagged neuropeptide Y (NPY) or brain-derived neurotrophic factor (BDNF). Conditional inactivation of *Munc18-1* abolished all DCV exocytosis. Expression of MUNC18-1, but not MUNC18-2 or MUNC18-3, supported DCV exocytosis in *Munc18-1* null neurons. Heterozygous (HZ) inactivation of *Munc18-1*, as a model for reduced MUNC18-1 expression, impaired DCV exocytosis, especially during the initial phase of train-stimulation, when the release was maximal. These data show that neurons critically and selectively depend on MUNC18-1 for neuropeptide secretion. Impaired neuropeptide secretion may explain aspects of the behavioral and neurodevelopmental phenotypes that were observed in *Munc18-1* HZ mice.

Key words: Munc18-1; dense-core vesicle; neuropeptide

Significance Statement

Neuropeptide secretion from dense-core vesicles (DCVs) modulates synaptic transmission, sleep, appetite, cognition and mood. However, the mechanisms of DCV exocytosis are poorly characterized. Here, we identify MUNC18-1 as an essential component for neuropeptide secretion from DCVs. Paralogs MUNC18-2 or MUNC18-3 cannot compensate for MUNC18-1. MUNC18-1 is the first protein identified to be essential for both neuropeptide secretion and synaptic transmission. In heterozygous (HZ) *Munc18-1* neurons, that have a 50% reduced MUNC18-1 expression and model the human STXBPI syndrome, DCV exocytosis is impaired, especially during the initial phase of train-stimulation, when the release is maximal. These data show that MUNC18-1 is essential for neuropeptide secretion and that impaired neuropeptide secretion on reduced MUNC18-1 expression may contribute to the symptoms of STXBPI syndrome.

Introduction

Neuropeptides control diverse brain functions such as memory, appetite, and mood (Cropper et al., 2018; Comeras et al., 2019;

Miranda et al., 2019), but the mechanisms that drive neuropeptide release from dense-core vesicles (DCVs) remain poorly understood. The principles of secretory vesicle exocytosis are well conserved and first characterized in yeast (Novick and Schekman, 1979; Novick et al., 1980, 1981; Aalto et al., 1993; Protopopov et al., 1993). Four canonical components appear to be essential in all types of regulated exocytosis: three SNARE proteins, of the (1) SNAP/SEC9 family; (2) the synaptobrevin/VAMP/SNC family; and (3) the syntaxin/SSO1/2 family; and (4) a SEC1/MUNC18 (SM) protein (Toonen and Verhage, 2003, 2007; Jahn and Scheller, 2006; Südhof and Rothman, 2009; Südhof, 2013; Kaeser and Regehr, 2014). While two of these canonical components have recently been identified for DCV exocytosis in mammalian neurons (Shimojo et al., 2015; Arora et al., 2017; Hoogstraaten et al., 2020), the participation of an SM protein has remained elusive.

Received Dec. 16, 2020; revised Apr. 29, 2021; accepted May 3, 2021.

Author contributions: D.C.P., S.A., M.F., R.F.T., and M.V. designed research; D.C.P., S.A., and M.F. performed research; S.A. and M.F. analyzed data; D.C.P., R.F.T., and M.V. wrote the paper.

This work was supported by the ERC Advanced Grant 322966 of the European Union (to M.V.). We thank RobbertZalm for cloning and producing viral particles, Lisa Laan and Desiree Schut for producing glia island cultures and providing primary culture assistance, Joke Wortel for organizing the animal breeding, Joost Hoetjes for genotyping, JurjenBroeke for technical support, Ingrid Saarloos for Western blottings, and members of the Center for Neurogenomics and Cognitive Research DCV team for discussions and helpful input.

The authors declare no competing financial interests.

Correspondence should be addressed to Matthijs Verhage at matthijs@cnrc.vu.nl or Ruud F. Toonen at ruud.toonen@cnrc.vu.nl.

<https://doi.org/10.1523/JNEUROSCI.3150-20.2021>

Copyright © 2021 the authors

Table 1. Statistical analysis summary and experimental design

Measurement	Condition	Value (mean ± SEM)	n	p value	Statistical test (test value)
DCV exocytosis per cell; Figure 1J	WT	41.4 ± 24.9	4 (21)	** <i>p</i> = 0.0024	Mann–Whitney test (53.5)
	<i>Munc18-1</i> null (conditional)	0.462 ± 0.877	4 (13)		
Neurite length; Figure 2D	<i>Munc18-1</i> null	2377 ± 160.4	4 (38)	n.s.: 1 vs 2, 1 vs 3, 2 vs 3	Kruskal–Wallis with Dunn's correction (0.040)
	(1) + MUNC18-1	2480 ± 245.1	4 (39)		
	(2) + MUNC18-2 (3) + MUNC18-3	2720 ± 324.2	4 (37)		
DCV exocytosis per cell; Figure 2G	<i>Munc18-1</i> null	62.1 ± 10.6	4 (38)	n.s.: 2 vs 3 *** <i>p</i> < 0.001: 1 vs 2, 1 vs 3	Kruskal–Wallis with Dunn's correction (65.8)
	(1) + MUNC18-1	7.05 ± 4.01	4 (39)		
	(2) + MUNC18-2 (3) + MUNC18-3	0.24 ± 0.09	4 (37)		
DCV poolsize; Figure 2H	<i>Munc18-1</i> null	3971 ± 327.7	4 (38)	n.s.: 1 vs 2, 1 vs 3, 2 vs 3	Kruskal–Wallis with Dunn's correction (2.15)
	(1) + MUNC18-1	3595 ± 522.0	4 (39)		
	(2) + MUNC18-2 (3) + MUNC18-3	4381 ± 558.4	4 (37)		
Release fraction; Figure 2I	<i>Munc18-1</i> null	0.0191 ± 0.0039	4 (38)	n.s.: 2 vs 3 *** <i>p</i> < 0.001: 1 vs 2, 1 vs 3	Kruskal–Wallis with Dunn's correction (65.3)
	(1) + MUNC18-1	0.0030 ± 0.0019	4 (39)		
	(2) + MUNC18-2 (3) + MUNC18-3	0.000 ± 0.000	4 (37)		
Early DCV exocytosis; Figure 3D	WT	0.238 ± 0.032	3 (30)	** <i>p</i> = 0.0069	Mann–Whitney test (225.5)
	<i>Munc18-1</i> HZ	0.117 ± 0.026	3 (26)		
DCV exocytosis per cell; Figure 3E	WT	79.1 ± 15.7	3 (30)	n.s. <i>p</i> = 0.502	Mann–Whitney test (336.5)
	<i>Munc18-1</i> HZ	57.2 ± 8.9	3 (26)		
DCV poolsize; Figure 3F	WT	3642 ± 411.6	3 (30)	n.s. <i>p</i> = 0.702	Mann–Whitney test (471)
	<i>Munc18-1</i> HZ	3528 ± 432.2	3 (26)		
Release fraction; Figure 3G	WT	0.0306 ± 0.0070	3 (30)	n.s. <i>p</i> = 0.598	Mann–Whitney test (437)
	<i>Munc18-1</i> HZ	0.0255 ± 0.0058	3 (26)		
DCV exocytosis delay; Figure 3H	WT	8.1 ± 0.9	3 (30)	* <i>p</i> = 0.0438	Mann–Whitney test (427)
	<i>Munc18-1</i> HZ	10.6 ± 0.8	3 (26)		
DCV exocytosis Stim. 1; Figure 4C	WT	118 ± 26.9	4 (35)	*** <i>p</i> = 0.0003	Mann–Whitney test (366.5)
	<i>Munc18-1</i> HZ	29.5 ± 5.00	4 (41)		
DCV exocytosis delay; Figure 4E	(1) WT 1st Stim.	6.0 ± 0.38	4 (35)	n.s.: 1 vs 2, 3 vs 4 *** <i>p</i> < 0.001: 1 vs 3, 2 vs 4	Kruskal–Wallis with Dunn's correction (58.8)
	(2) HZ 1st Stim.	6.6 ± 0.36	4 (40)		
	(3) WT 2nd Stim.	3.0 ± 0.30	4 (35)		
	(4) HZ 2nd Stim.	3.5 ± 0.24	4 (39)		
DCV exocytosis Stim. 2; Figure 4F	WT	105 ± 35.7	4 (35)	** <i>p</i> = 0.0028	Mann–Whitney test (430.5)
	<i>Munc18-1</i> HZ	33.9 ± 5.44	4 (41)		
Potentiation; Figure 4G	WT	0.97 ± 0.10	4 (35)	** <i>p</i> = 0.0077	Mann–Whitney test (423)
	<i>Munc18-1</i> HZ	1.60 ± 0.20	4 (41)		
Poolsize; Figure 4H	WT	4224 ± 339	4 (35)	n.s. <i>p</i> = 0.223	Mann–Whitney test (600)
	<i>Munc18-1</i> HZ	3888 ± 360	4 (41)		
Release fraction Stim. 1; Figure 4I	WT	0.0348 ± 0.0079	4 (35)	** <i>p</i> = 0.0028	Mann–Whitney test (430)
	<i>Munc18-1</i> HZ	0.0104 ± 0.0024	4 (41)		
Release fraction Stim. 2; Figure 4J	WT	0.0284 ± 0.0078	4 (35)	* <i>p</i> = 0.0416	Mann–Whitney test (521.5)
	<i>Munc18-1</i> HZ	0.0120 ± 0.0024	4 (41)		
DCV exocytosis meta-analysis; Figure 5C	WT	86.7 ± 15.5	7 (67)	*** <i>p</i> = 0.0006	Mann–Whitney test (1551)
	<i>Munc18-1</i> HZ	31.5 ± 3.88	7 (70)		
DCV poolsize meta-analysis; Figure 5D	WT	3946 ± 265.0	7 (67)	n.s. <i>p</i> = 0.338	Mann–Whitney test (2122)
	<i>Munc18-1</i> HZ	3739 ± 275.2	7 (70)		
Neurite length; Figure 5E	WT	2525 ± 152.6	7 (70)	n.s. <i>p</i> = 0.0631	Mann–Whitney test (2064)
	<i>Munc18-1</i> HZ	2185 ± 134.3	7 (72)		
Release fraction; Figure 5F	WT	0.0284 ± 0.0049	7 (67)	** <i>p</i> = 0.0039	Mann–Whitney test (1675)
	<i>Munc18-1</i> HZ	0.0129 ± 0.0022	7 (70)		
BDNF-pHluorin exocytosis Stim. 1; Figure 6C	WT	233 ± 31.0	4 (45)	* <i>p</i> = 0.0230	Mann–Whitney test (659)
	<i>Munc18-1</i> HZ	118 ± 13.2	4 (41)		
BDNF-pHluorin exocytosis Stim. 2; Figure 6D	WT	182 ± 24.0	4 (45)	n.s. <i>p</i> = 0.1336	Mann–Whitney test (748.5)
	<i>Munc18-1</i> HZ	127 ± 16.3	4 (41)		
Potentiation BDNF-pHluorin; Figure 6E	WT	0.878 ± 0.061	4 (45)	* <i>p</i> = 0.0300	Mann–Whitney test (671)
	<i>Munc18-1</i> HZ	1.175 ± 0.108	4 (41)		

(Table continues.)

Table 1. Continued

Measurement	Condition	Value (mean ± SEM)	<i>n</i>	<i>p</i> value	Statistical test (test value)
BDNF-pHluorin exocytosis delay; Figure 6G	(1) WT 1st Stim.	4.7 ± 0.2	4 (45)	n.s.: 1 vs 2, 3 vs 4	Kruskal–Wallis with Dunn's correction (83)
	(2) HZ 1st Stim.	5.2 ± 0.3	4 (41)		
	(3) WT 2nd Stim.	2.5 ± 0.1	4 (45)	3, 2 vs 4	
	(4) HZ 2nd Stim.	2.8 ± 0.2	4 (40)		
DCV poolsize BDNF-pHluorin; Figure 6H	WT	3947 ± 275.1	4 (45)	n.s. <i>p</i> = 0.2895	Mann–Whitney test (669.5)
	<i>Munc18-1</i> HZ	3514 ± 236.7	4 (41)		
BDNF-pHluorin release fraction Stim. 1; Figure 6I	WT	0.0586 ± 0.0066	4 (45)	* <i>p</i> = 0.0449	Mann–Whitney test (690)
	<i>Munc18-1</i> HZ	0.0372 ± 0.0043	4 (41)		
BDNF-pHluorin release fraction Stim. 2; Figure 6J	WT	0.0466 ± 0.0055	4 (45)	n.s. <i>p</i> = 0.3920	Mann–Whitney test (823)
	<i>Munc18-1</i> HZ	0.0383 ± 0.0046	4 (41)		

The conditions, values, sample sizes, *p* values, and statistical test are represented for each measurement. *n* = number of independent experiments (number of cells); n.s. = non-significant, *p* values were calculated in GraphPad prism

In mammals, seven SM proteins are expressed: mSly1, mVPS33A, mVPS33B, mVPS45, MUNC18-1, MUNC18-2, and MUNC18-3. The first four control internal membrane trafficking, while the three MUNC18 proteins control exocytosis (for a review, see Toonen and Verhage, 2003). MUNC18 proteins bind syntaxins (Thurmond et al., 1998; Misura et al., 2000; Kauppi et al., 2002; Dulubova et al., 2007; Burkhardt et al., 2008; Bin et al., 2013), promote docking of secretory vesicles (Voets et al., 2001; de Wit et al., 2009) and probably serve as a template for SNARE-complex assembly, which drives exocytosis (Parisotto et al., 2014; Sitariska et al., 2017; Jiao et al., 2018; Meijer et al., 2018; Wang et al., 2019; André et al., 2020). MUNC18-2 acts in blood platelets, cytotoxic T lymphocytes, natural killer cells and mast cells (Côte et al., 2009; Hackmann et al., 2013; Gutierrez et al., 2018; Cardenas et al., 2019); MUNC18-3 in adipocytes (Tamori et al., 1998; Thurmond et al., 2000); and MUNC18-1 in chromaffin cells and the posterior pituitary (Voets et al., 2001; Korteweg et al., 2005) and in synaptic vesicle (SV) exocytosis in neurons (Verhage et al., 2000). In other cell types, such as lung mucus cells and pancreatic β -cells, multiple MUNC18 paralogs support different phases of secretion in the same pathway (Oh and Thurmond, 2009; Oh et al., 2012; Lam et al., 2013; Jaramillo et al., 2019). In neurons, all three MUNC18 paralogs are expressed, but MUNC18-1 has a ~10-fold higher expression and is the only paralog that supports neurotransmission (Verhage et al., 2000; Yue et al., 2014; Zeisel et al., 2015; He et al., 2017; Santos et al., 2017). Which SM-protein(s) support DCV exocytosis is unknown.

To identify which SM protein(s) support DCV exocytosis in neurons, we analyzed DCV fusion with single vesicle resolution using three fluorescent DCV-fusion reporters in primary neurons from homozygous and heterozygous (HZ) *Munc18-1* null mutant mice. We found that *Munc18-1* inactivation abolished neuropeptide release and that expression of MUNC18-2 or MUNC18-3 did not restore DCV exocytosis. HZ *Munc18-1* inactivation reduced DCV exocytosis. We conclude that neurons critically and specifically depend on MUNC18-1 for neuropeptide secretion.

Materials and Methods

Animals

Animal housing and breeding was in line with institutional and Dutch governmental guidelines and all procedures were approved by the ethical committee of the Vrije Universiteit University/Vrije Universiteit Medical Center (license number: DEC-FGA 11-03 and AVD112002017824).

Munc18-1^{lox/lox} mice (Heeroma et al., 2004) and *Munc18-1* null mice [Munc18-1 knock-out (KO); Verhage et al., 2000; Toonen et al., 2006b] were generated as described before. To obtain *Munc18-1* conditional KO (cKO) primary cultures, *Munc18-1*^{lox/lox} mice were time-mated and P1 pups were used for dissection of the hippocampi. For *Munc18-1* wild-type (WT), *Munc18-1* KO, and *Munc18-1* HZ primary cultures, *Munc18-1* HZ mice were time-mated and embryonic day (E)18 pups were collected via caesarean section, after which they were used for dissection of the hippocampi. All pups were genotyped before culturing and were of unknown sex.

Neuron culture

Preparation of dissociated hippocampal neuron cultures was performed as reported before (De Wit et al., 2009; Farina et al., 2015). In brief, isolated hippocampi were digested with 0.25% trypsin (Life Technologies) for 20 min at 37°C in HBSS (Sigma) with 10 mM HEPES (Life Technologies). After 3× washing and trituration, 1000–2000 neurons were plated per well onto pregrown glia microislands. These were generated by stamping agarose coated 18 mm glass coverslips with a solution of 0.5 mg/ml poly-D-lysine (Sigma), 3.5 mg/ml rat tail collagen (BD Biosciences), and 17 mM acetic acid onto which 6.000 rat glia were plated (Mennerick et al., 1995; Wierda et al., 2007).

Viruses

All constructs were generated with sequence verification, cloned into a pLenti vector containing a Synapsin promoter. To obtain *Munc18-1* cKO and control neurons, Cre recombinase and defective Cre (deltaCre; Kaeser et al., 2011; Persoon et al., 2019) were delivered into *Munc18-1*^{lox/lox} neurons via lenti-virus particles at day *in vitro* (DIV)8. Imaging was performed at DIV15, when synaptic transmission was absent, but before neuronal degeneration occurred. Lentiviral neuropeptide Y (NPY)-mCherry was used as a marker for neuropeptide release as reported before (van de Bospoort et al., 2012; Persoon et al., 2018) and Synaptophysin-pHluorin as a marker for synaptic transmission (Granseth et al., 2006).

To rescue *Munc18-1* KO neurons with the paralogs MUNC18-1, MUNC18-2, or MUNC18-3, we used previously described MUNC18-1, MUNC18-2, and MUNC18-3 plasmids (Toonen et al., 2006b; He et al., 2017; Santos et al., 2017) with Cre-EGFP co-expressed via a T2A cleavage-peptide sequence. Cre-EGFP fluorescence is confined to the nucleus and therefore does not preclude pHluorin-based DCV exocytosis analysis. *Munc18-1* KO neurons were infected with these paralogs at DIV0 to ensure neuronal survival and viral concentrations were adjusted until similar survival rates were observed between conditions. For *Munc18-1* KO rescue experiments and *Munc18-1* HZ experiments, NPY-pHluorin and brain-derived neurotrophic factor (BDNF)-pHluorin were used as described before (De Wit et al., 2009; van de Bospoort et al., 2012; Farina et al., 2015; Persoon et al., 2018, 2019).




Figure 1. *Munc18-1* is essential for DCV exocytosis in neurons. **A**, Schematic representation of a primary mouse hippocampal neuron grown on a glia microisland. **B**, The kymograph shows NPY-mCherry fluorescence in an axonal stretch over time. During high-frequency train-stimulation indicated by blue bars (16 trains of 50 APs at 50 Hz), NPY-mCherry release events are visible as an abrupt termination of the line, marked by arrowheads. Below, Schematic model of an NPY-mCherry release event. **C**, Disappearance of a NPY-mCherry punctum visualized by two still frames: one before and one after the indicated exocytosis event (red arrowhead, same event as in **B**). The typical trace shows the change in fluorescence (ΔF) over time measured from the indicated exocytosis event. **D**, Isolated *Munc18-1* cKO and WT (control) neurons infected at DIV8 with Cre-EGFP were tested for viability (+ = viable, – = non-viable) and for SV exocytosis using Synaptophysin-pHluorin (SyPhy). **E**, Typical Ca^{2+} traces during high-frequency burst-stimulation (16 trains of 50 APs at 50 Hz, blue bars), obtained using Fluo5-AM, which increases fluorescence on Ca^{2+} binding, in DIV14–DIV15 *Munc18-1* cKO (+ Cre-EGFP) and WT (– Cre-EGFP) neurons. **F**, SV exocytosis assessed using SyPhy in *Munc18-1* cKO (+ Cre-EGFP) and WT (– Cre-EGFP) neurons. Fluorescence intensity increase reports SV exocytosis. NH_4^+ is superfused at second 85 (indicated by gray shading) to dequench SyPhy fluorescence in all SVs. **G**, Quantification of **F**: $\Delta F_{\text{max}}/\Delta \text{NH}_4^+$ of SyPhy in *Munc18-1* cKO and WT neurons. **H**, Histogram of the average number of DCV exocytosis events over time from non-silent *Munc18-1* cKO neurons infected with ΔCre (WT) or Cre (cKO). The blue bars indicate the stimulation paradigm. Sample size excluding silent neurons is visualized as n/N . **I**, Cumulative representation of the data in **H**. Error bars are SEM. **J**, The Tukey/scatter plot shows that the total number of DCV exocytosis events per cell is severely reduced in *Munc18-1* cKO neurons (sample size is visualized as n/N). Mann–Whitney U test: $**p < 0.01$.

Western blotting

Munc18-1 null (KO) neurons were infected at DIV0 with *Munc18-1*, *Munc18-2*, or *Munc18-3* containing lentiviral particles and harvested by scraping in ice-cold PBS at DIV14. Samples were centrifuged (12,000 rpm, 5 min) and lysed in Laemmli sample buffer containing 2% SDS (VWR chemicals, M107), 10% glycerol (Merck, 818709), 0.26 M β -mercaptoethanol (Sigma, M3148), 60 mM Tris-HCl (Serva, 37180) pH 6.8, and 0.01% bromophenol blue (Applichem, A3640). E18 brains from *Munc18-1* KO and WT littermate and the spleen from an E18 WT embryo were triturated in ice-cold PBS before lysis in Laemmli sample buffer. Lysates were separated on 8% SDS-polyacrylamide gels. Proteins were transferred overnight at 150 mA and 4°C via wet-blot transfer. Blocking was done with 2% BSA (Acros Organics, 268131000) in PBS with 0.1% Tween 20 for 4 h at room temperature (RT). Blots were incubated with polyclonal *Munc18-1* (SySy 116003; Cijssouw et al., 2014; 1:1000), *Munc18-2* (SySy 116102; 1:500), or *Munc18-3* (Sigma HPA027255; 1:500) antibodies. Mouse monoclonal γ -Tubulin antibody (Sigma; T5326; 1:1000) was used as control for total protein levels. After washing with PBS + 0.1% Tween 20, the blots were incubated with secondary antibodies (goat anti-mouse or anti-rabbit alkaline phosphatase-conjugated secondary antibodies 1:10,000; Jackson immunoresearch) in PBS with 2% BSA and 0.1% Tween 20 for 45 min at 4°C. After washing, blots were incubated with AttoPhos substrate for 5 min, scanned on a Fujifilm FLA-5000 Reader and analyzed with ImageJ software.

Live imaging

All live imaging experiments were performed between DIV14 and DIV18 at RT (21–26°C). We used a custom-built set-up including an inverted microscope (IX81; Olympus) with an MT20 light source (Olympus), the appropriate filter sets (Semrock), a 40 \times oil objective (NA 1.3), an EM charge-coupled device camera (EMCCD; C9100-02; Hamamatsu Photonics) and Xcellence RT imaging software (Olympus). Electrical stimulation was delivered by parallel platinum electrodes placed around the glia-island, conducting 30 mA, 1-ms pulses controlled by a Master 8 system (AMPI) and a stimulus generator (A385RC, World Precision Instruments). A total of 16 or eight trains of 50 action potentials (APs) were generated at 50 Hz with 0.5-s interval after 30 s of baseline recording. Imaging acquisition rate was 2 Hz.

Coverslips were perfused with Tyrode's solution (2 mM CaCl_2 , 2.5 mM KCl, 119 mM NaCl, 2 mM MgCl_2 , 30 mM glucose, and 25 mM HEPES; pH 7.4). pHluorin-based DCV exocytosis assays ended with a 10 s NH_4^+ perfusion (Tyrode's solution with 50 mM NH_4Cl , replacing 50 mM NaCl), delivered via a gravity flow system with a capillary placed above the neuron, to de-quench pHluorin in all DCVs.

Analysis

In ImageJ (NIH), 2 \times 2 pixel regions were placed on NPY-mCherry DCV exocytosis




Figure 2. Expression of MUNC18-1, but not MUNC18-2 or MUNC18-3, supports DCV exocytosis in *Munc18-1* null neurons. **A**, left, Model showing the DCV cargo NPY-pHluorin quenched at the low pH inside the vesicle, and de-quenched on vesicular pH elevation during an exocytosis event or NH₄⁺ application. Right, Still frames show an axonal stretch before and during stimulation, and during NH₄⁺ perfusion. The line plots show changes in fluorescence (ΔF) over time measured from the exocytosis events indicated by the green arrows. Scale bar: 5 μ m. **B**, The kymograph shows an axonal stretch over time, visualizing NPY-pHluorin de-quenching events (arrowheads), caused by DCV exocytosis, as well as de-quenching caused by NH₄⁺ (depicted by green-shading at the bottom). High-frequency train-stimulation is indicated with blue bars. The green arrowheads indicate the same exocytosis events as in **A**. The black arrows indicate other visible exocytosis events. **C**, Lysates of primary WT neurons, *Munc18-1* null (KO) neurons (DIV14–DIV18) or mouse spleen were separated via SDS-PAGE gel electrophoresis and immunoblotted for MUNC18-1 (M18-1), MUNC18-2 (M18-2), or MUNC18-3 (M18-3), and for γ -Tubulin (Tubulin) as loading control. Rescue of *Munc18-1* KO neurons (indicated with KO + rescue, third lane) was done with Munc18-1 (top), Munc18-2 (middle), or Munc18-3 (bottom) containing lentivirus particles at DIV0. Ratio indicates intensity of MUNC18-1, MUNC18-2, or MUNC18-3 divided by tubulin, showing that MUNC18-1 rescue levels were higher than WT and that MUNC18-2 rescue levels were higher, while MUNC18-3 rescue levels were lower than endogenous levels in the spleen. **D**, The Tukey/scatter plot shows that the total neurite length of *Munc18-1* null neurons rescued with MUNC18-1, MUNC18-2, or MUNC18-3 is similar (same data set as in Fig. 2). Kruskal–Wallis with Dunn’s correction: n.s. = non-significant. **E**, Histogram showing the average number of NPY-pHluorin-labeled DCV exocytosis events in *Munc18-1* null neurons rescued with

events and 3×3 pixel regions were placed on NPY-pHluorin or BDNF-pHluorin events. The ROI intensity measures were loaded into a custom written MATLAB (MathWorks) script for semi-automatic analysis, where each was plotted as change in fluorescence (ΔF) compared with baseline fluorescence (F0, average fluorescence during the first 10 frames). An exocytosis event was detected when ΔF was at least 2 SDs below or above F0 for respectively NPY-mCherry and NPY/BDNF-pHluorin-labeled DCVs. Somatic events were excluded because of high background signal. Histograms and cumulative plots were generated in MATLAB. Further analysis including statistical tests and generation of Tukey/scatter plots was conducted in GraphPad Prism. The onset delay in DCV exocytosis was calculated for each neuron by subtracting the time point of the start of the simulation from the time point where 50% of the events have occurred.

To calculate the neurite length and total number of DCVs (poolsize) per neuron, the highest-intensity frame during NH_4 perfusion was taken for pHluorin based assays and further analyzed using the MATLAB program SynD (Schmitz et al., 2011; van de Bospoort et al., 2012). Parameters were optimized for detection of DCVs and the number of detected DCVs was adjusted for intensity by dividing by the mode intensity.

Experimental design and statistical analysis

Statistical analysis was performed in GraphPad Prism (summarized in Table 1, which also includes experimental design). Shapiro-Wilk normality test was used to test for normal distributions and Levene's to test for homogeneity of variances. In all datasets at least one group was not normally distributed. Therefore, a Mann-Whitney *U* test for data with two conditions and multiple comparisons were tested using a Kruskal-Wallis test followed by a Dunn's multiple comparisons *post hoc* test.

Results

Munc18-1 is essential for DCV exocytosis in neurons

To test which SM protein(s) drives DCV exocytosis in mammalian neurons, we used hippocampal neurons from conditional *Munc18-1 null* (cKO) mice grown on prepatterned glia microislands, each containing a single neuron infected with NPY-mCherry as a DCV exocytosis reporter (De Wit et al., 2009; Farina et al., 2015; Persoon et al., 2018; Fig. 1A). Neurons were infected with EGFP-tagged Cre-recombinase at DIV8 to induce *Munc18-1 null*, or with ineffective deltaCre (WT) as control. DCV exocytosis was triggered by high-frequency burst-stimulation (16×50 APs at 50 Hz; Fig. 1B) and individual release events, marked as sudden disappearance of mCherry fluorescence, were quantified over time (Fig. 1C).

As MUNC18-1 is essential for SV exocytosis (Verhage et al., 2000), we used the fluorescent SV exocytosis reporter Synaptophysin-pHluorin (Granseth et al., 2006) to assess the Cre-dependent loss of MUNC18-1 protein in *Munc18-1* cKO

neurons. SV exocytosis was marked as an increase in fluorescence during burst stimulation in control neurons at DIV15 and was blocked in *Munc18-1* cKO neurons that were infected 7 d earlier with Cre-EGFP, while calcium influx during stimulation was not significantly affected (Fig. 1D–G). In sister cultures at DIV15, control neurons showed NPY-mCherry release events throughout the 50 Hz burst stimulation, with the highest rate during the first few bursts, as shown before (Fig. 1H,I; Farina et al., 2015; Persoon et al., 2018, 2019). In contrast, virtually no NPY-mCherry release events occurred in *Munc18-1* cKO neurons (Fig. 1H–J). Not a single release event was observed in 75% of these neurons (Fig. 1J). Hence, MUNC18-1 is essential for neuronal DCV exocytosis.

Expression of MUNC18-1, but not MUNC18-2 or MUNC18-3, supports DCV exocytosis in *Munc18-1 null* neurons

For independent confirmation of the DCV exocytosis defect in *Munc18-1* cKO neurons, we next used a different DCV exocytosis reporter in classical *Munc18-1 null* neurons. The pH-sensitive DCV exocytosis reporter NPY-pHluorin, which has low basal fluorescence because of quenching at the low pH inside DCVs, and detects DCV fusion pore opening (van de Bospoort et al., 2012; Farina et al., 2015; Persoon et al., 2018). During high-frequency burst-stimulation, NPY-pHluorin marks DCV exocytosis events by a sudden increase in fluorescence on DCV fusion with the plasma membrane, followed by an immediate decrease (transient events representing fusion pore closure and vesicle reacidification or full cargo release) or delayed decrease (persistent events representing delayed reacidification or extracellular cargo deposition; Fig. 2A,B). To visualize the total DCV pool, neurons were superfused with NH_4^+ at the end of each recording, de-quenching NPY-pHluorin in acidified compartments (Fig. 2A,B).

Munc18-1 null neurons degenerate *in vitro* and *in vivo*, which can be delayed by the trophic factors insulin and BDNF (Verhage et al., 2000; Heeroma et al., 2004). Viral expression of MUNC18-1, or its paralogs MUNC18-2 or MUNC18-3 completely rescues cell viability (He et al., 2017; Santos et al., 2017). To test which paralogs support DCV exocytosis, we expressed each paralog separately in *Munc18-1 null* neurons and quantified DCV exocytosis with NPY-pHluorin. All MUNC18 paralogs were detected on Western-blot, supported normal viability and neurons expressing any of these paralogs had a normal morphology, as reported before (Fig. 2C,D). Re-expression of MUNC18-1 in *Munc18-1 null* neurons resulted in robust DCV exocytosis on high-frequency burst-stimulation (Fig. 2E–G), comparable to WT neurons (see below). However, DCV exocytosis was severely impaired on expression of MUNC18-2 or MUNC18-3 (Fig. 2E–G). Not a single fusion event was observed in 56% (MUNC18-2) and 81% (MUNC18-3) of the neurons (Fig. 2G). The total number of DCVs per neuron (DCV poolsize) was similar in all three conditions (Fig. 2H). DCV exocytosis normalized to the poolsize (release fraction) was normal in *Munc18-1 null* neurons re-expressing MUNC18-1, but severely impaired in *Munc18-1 null* neurons expressing MUNC18-2 or MUNC18-3 (Fig. 2I). These data show that MUNC18-1 re-expression supports stimulus-evoked DCV exocytosis in *Munc18-1 null* neurons and that MUNC18-2 and MUNC18-3 do not support DCV exocytosis. In addition, MUNC18-1, MUNC18-2, and MUNC18-3 all support normal morphology and DCV biogenesis in *Munc18-1 null* neurons.

←

MUNC18-1 (black), MUNC18-2 (green), or MUNC18-3 (brown). Sample size is indicated per condition as *n/N*. The blue bars indicate the stimulation paradigm. Error bars are SEM. **F**, Cumulative representation of the data in **D**. Error bars are SEM. **G**, The Tukey/scatter plot shows that *Munc18-1 null* neurons rescued with MUNC18-2 or MUNC18-3 have a strong reduction in the total number of DCV exocytosis events per cell compared with MUNC18-1 rescued neurons. Kruskal–Wallis with Dunn's correction: ****p* < 0.001. n.s. = non-significant, *p* > 0.05. **H**, The Tukey/scatter plot shows that the total pool of DCVs per cell, revealed by NH_4 application, is similar in *Munc18-1 null* neurons rescued with MUNC18-1, MUNC18-2, or MUNC18-3. Kruskal–Wallis with Dunn's correction: n.s. = non-significant. **I**, The Tukey/scatter plot shows that in MUNC18-2 or MUNC18-3 rescued neurons, the number of DCV exocytosis events normalized by the poolsize (indicated as release fraction) is strongly reduced. Kruskal–Wallis with Dunn's correction: ****p* < 0.001, n.s. = non-significant.

Reduced expression in *Munc18-1* HZ neurons leads to decreased DCV exocytosis

To characterize the role of MUNC18-1 in DCV exocytosis further, we quantified exocytosis events of NPY-pHluorin-labeled DCVs under conditions of reduced expression in *Munc18-1* HZ neurons, which are shown to have ~50% reduced MUNC18-1 expression levels (Toonen et al., 2006b; Kovacevic et al., 2018). First, *Munc18-1* WT and *Munc18-1* HZ neurons were stimulated with a high-frequency burst-stimulation (16 × 50 APs at 50 Hz). *Munc18-1* HZ neurons showed a trend toward reduced DCV exocytosis, especially during the first two bursts (2 × 50 APs; Fig. 3*A,B*). *Post hoc* analysis of this initial phase indicated a 61% reduction in initial DCV exocytosis in *Munc18-1* HZ neurons (Fig. 3*C,D*). The median DCV exocytosis onset delay, defined as the duration from the start of the stimulation until 50% of the DCV exocytosis events have occurred, was increased in *Munc18-1* HZ (Fig. 3*E*). The total number of exocytosis events, the total DCV pool and release fraction were all not altered (Fig. 3*F–H*).

To seek independent confirmation of these effects, we stimulated *Munc18-1* WT and HZ neurons in a new series of experiments with half the number of bursts (eight instead of 16), the same number of APs per burst (50) and the same frequency (50 Hz), followed by the same pattern 30 s later. DCV exocytosis in *Munc18-1* HZ neurons was reduced throughout the first 8-burst train-stimulation, by 79% (Fig. 4*A–C*; Movies 1, 2). During this first 8-burst train-stimulation, the onset of exocytosis events was unaltered in *Munc18-1* HZ neurons compared with WT neurons (Fig. 4*A,B,D,E*). During the subsequent (second) eight-burst train-stimulation, both *Munc18-1* WT and HZ neurons showed acceleration of DCV exocytosis compared with the first train-stimulation, indicated by a strong reduction in the median delay of DCV exocytosis relative to the start of the train-stimulation (Fig. 4*A,B,D,E*). DCV exocytosis was again reduced in HZ neurons during the second stimulation, with a smaller effect size than during the first stimulation (60% reduction; Fig. 4*A,B,F*; Movies 1, 2), resulting in a median reduction of 69% over the two eight-trains. As a measure for potentiation of DCV exocytosis, the number of exocytosis events during the second stimulation was divided by the number of events




Figure 3. Reduced MUNC18-1 levels decrease DCV exocytosis during the first seconds of stimulation. **A**, The histogram shows the average number of DCV exocytosis events for *Munc18-1* WT (black) and *Munc18-1* HZ (blue) neurons over time (sample size is indicated as *n/N*). Error bars are SEM. **B**, Cumulative representation of the data in **A**. Error bars are SEM. WT exocytosis levels varied between experiments, probably because of changes in medium batches. **C**, Normalized cumulative representation of the data in **A** during the first seconds of train-stimulation. Error bars are SEM. **D**, The Tukey/scatter plot shows that the relative DCV exocytosis during the first two trains of stimulation is decreased in *Munc18-1* HZ neurons. This was calculated per cell by dividing the number of events during the first two seconds of stimulation by the total number of exocytosis events of that cell. Mann–Whitney test: $**p < 0.01$. **E**, The Tukey/scatter plot shows that the median delay of DCV exocytosis events relative to the start of the train-stimulation is larger in *Munc18-1* HZ neurons compared to WT. Mann–Whitney test: $*p < 0.05$. **F**, The Tukey/scatter plot shows the number of DCV exocytosis events for *Munc18-1* WT and HZ neurons. Mann–Whitney test: n.s. = non-significant. **G**, The Tukey/scatter plot shows the total number of DCVs, extracted from NH_4^+ superfusion at the end of each recording, for *Munc18-1* WT and HZ neurons. Mann–Whitney test: n.s. = non-significant. **H**, The Tukey/scatter plot shows the number of DCV exocytosis events normalized by the poolsize (release fraction) for *Munc18-1* WT and HZ neurons. Mann–Whitney test: n.s. = non-significant.






Figure 4. *Munc18-1* HZ inactivation reduces exocytosis of NPY-pHluorin-labeled DCVs. **A**, The histogram shows the average number of DCV exocytosis events for *Munc18-1* WT (black) and HZ (blue) neurons that were infected with NPY-pHluorin (sample size is indicated as *n*/*N*). The blue bars indicate the two stimulation paradigms (8 times 50 APs at 50 Hz). Error bars are SEM. **B**, Cumulative representation of the data in **A**. Error bars are SEM. **C**, The Tukey/scatter plot shows that the number of DCV exocytosis events per cell during the first train-stimulation is decreased in *Munc18-1* HZ neurons. Mann–Whitney *U* test: ****p* < 0.001. In this experiment, *Munc18-1* WT neurons had higher absolute numbers of DCV exocytosis compared with those in Figure 3. **D**, Normalized cumulative representation of the data in **A**. Error bars are SEM. **E**, The Tukey/scatter plot shows the median delay of DCV exocytosis events, relative to the start of each train-stimulation, for *Munc18-1* WT and HZ neurons. The delay within each train-stimulation is similar between *Munc18-1* WT and HZ neurons. During the second train-stimulation, in both WT and HZ neurons, the median delay of exocytosis is decreased compared with the first stimulation. Kruskal–Wallis with Dunn’s correction: ****p* < 0.001, n.s. = non-significant. **F**, The Tukey/scatter plot shows that the number of DCV exocytosis events per cell during the second train-stimulation is decreased in *Munc18-1* HZ neurons. Mann–Whitney *U* test: ***p* < 0.01. **G**, The Tukey/scatter plot shows that the ratio of the number of exocytosis events between the second and first train-stimulation (potentiation) is higher in *Munc18-1* HZ neurons. Mann–Whitney *U* test: ***p* < 0.01. **H**, The Tukey/scatter plot shows that *Munc18-1* WT and HZ neurons have a similar total pool of DCVs, as revealed by NH₄ application. Mann–Whitney *U* test: n.s. = non-significant. **I**, The Tukey/scatter plot shows that the number of DCV exocytosis events normalized by the total pool (indicated as release fraction) was decreased in *Munc18-1* HZ neurons during the first train-stimulation. Mann–Whitney *U* test: ***p* < 0.01. **J**, The Tukey/scatter plot shows that the number of DCV exocytosis events normalized by the total pool (indicated as release fraction) was decreased in *Munc18-1* HZ neurons during the second train-stimulation. Mann–Whitney *U* test: **p* < 0.01.



Movie 1. NPY-pHluorin-labeled DCV exocytosis events in WT neuron. Neuron was stimulated with two episodes consisting of eight bursts of 50 APs at 50 Hz. The first episode of train-stimulation starts at 30 s, the second stimulation starts 30 s after the end of the first stimulation (which is at 72 s). NPY-pHluorin-labeled DCV exocytosis events are visible as appearing puncta, mostly during the train-stimulations. From 113 s, NH_4^+ perfusion starts, which dequenches all NPY-pHluorin in acidic compartments, labeling the total DCV pool. [View online]



Movie 2. NPY-pHluorin-labeled DCV exocytosis events in *Munc18-1* HZ neuron. Neuron was stimulated with two episodes consisting of eight bursts of 50 APs at 50 Hz. The first episode of train-stimulation starts at 30 s, the second stimulation starts 30 s after the end of the first stimulation (which is at 72 s). NPY-pHluorin-labeled DCV exocytosis events are visible as appearing puncta, mostly during the train-stimulations. From 113 s, NH_4^+ perfusion starts, which dequenches all NPY-pHluorin in acidic compartments, labeling the total DCV pool. [View online]

during the first stimulation. DCV exocytosis in *Munc18-1* HZ neurons showed a potentiation effect during the second train-stimulation, whereas this was absent in WT neurons (Fig. 4G). The total DCV pool was similar between genotypes (Fig. 4H). Consequently, DCV exocytosis normalized by the poolsize was significantly reduced during both stimulations in *Munc18-1* HZ neurons (Fig. 4I,J).

To assess the overall effect of reduced MUNC18-1 expression on DCV exocytosis in both datasets (Figs. 3, 4), we performed a meta-analysis combining the data of the first eight bursts of 50 APs from both experiments. This analysis revealed that DCV exocytosis was reduced by 56% during the first eight bursts of high-frequency stimulation (Fig. 5A–C). The total number of DCVs and the total neurite length were not altered, and as a consequence, DCV exocytosis normalized to the total DCV pool was reduced by 56% (Fig. 5D–F). Taken together, these data show that HZ inactivation of *Munc18-1* decreased DCV exocytosis, with a relatively stronger effect during the first stimulation, while acceleration of DCV exocytosis during the second stimulation stayed intact.

Finally, to test whether the reduction of DCV exocytosis in *Munc18-1* HZ neurons generalizes to different DCV cargo types, we used the neurotrophin release reporter BDNF-pHluorin as an alternative DCV cargo. The total number of BDNF-pHluorin exocytosis events in both genotypes was at least twice as high as with NPY-pHluorin (Figs. 4A,B,C,F, 6A–D). *Munc18-1* HZ neurons expressing BDNF-pHluorin and stimulated with two episodes of eight-burst train-stimulation of 50 APs at 50 Hz showed a 36% reduced DCV exocytosis during the first stimulation, with a similar, albeit smaller, effect during the second stimulation (Fig. 6A–D), resulting in a median reduction of 43% over the two eight-trains compared with WT. Exocytosis in *Munc18-1* HZ neurons was potentiated during the second train-stimulation, whereas this effect was absent in WT neurons (Fig. 6E). The acceleration of release during the second eight-train was similar to the previous experiment using NPY-pHluorin and similar for both genotypes (Fig. 6F,G). The total DCV pool was again similar between experimental groups and consequently DCV exocytosis normalized to the total pool was reduced during the first stimulation, but less pronounced during the second stimulation (Fig. 6H–J). Hence, HZ inactivation of *Munc18-1* and a 50% reduced protein level decreased DCV exocytosis substantially, independent of DCV cargo, with a relatively stronger effect during the first stimulation.

Discussion

Here, we report that MUNC18-1 is essential for DCV exocytosis in hippocampal neurons. Live imaging of fluorescent reporters showed that *Munc18-1* inactivation abolished neuropeptide release. Expression of paralogs MUNC18-2 or MUNC18-3 did restore cell viability but not DCV exocytosis. Furthermore, *Munc18-1* HZ inactivation impaired DCV exocytosis. Hence, neurons critically and selectively depend on MUNC18-1 for DCV exocytosis.

We previously showed that neurotransmitter secretion critically depends on MUNC18-1 (Verhage et al., 2000). Our current data demonstrates that this is also true for neuropeptide secretion (Figs. 1, 2). SVs and DCVs share many other components of their exocytosis machinery (van de Bospoort et al., 2012; Cao et al., 2013; Südhof, 2013; Farina et al., 2015; Shimojo et al., 2015; Arora et al., 2017; Persoon et al., 2019; Hoogstraaten et al., 2020); however, several properties are strikingly different. DCVs require




Figure 5. Meta-analysis: *Munc18-1* HZ inactivation reduces DCV exocytosis. **A**, The histogram shows the average number of DCV exocytosis events of *Munc18-1* WT (black) and HZ (blue) neurons infected with NPY-pHluorin (sample size is indicated as *n/N*), during the first eight bursts of high-frequency train-stimulation (combined meta-analysis of datasets from Figs. 3, 4). Error bars are SEM. **B**, Cumulative representation of the data in **A**. Error bars are SEM. **C**, The Tukey/scatter plot shows that the number of DCV exocytosis events is decreased in *Munc18-1* HZ neurons during the first eight bursts of high-frequency train-stimulation. Mann–Whitney *U* test: ****p* < 0.001. **D**, The Tukey/scatter plot shows the total number of DCVs for *Munc18-1* WT and HZ neurons, revealed by NH_4^+ superfusion. Mann–Whitney *U* test: n.s. = non-significant. **E**, The Tukey/scatter plot shows the total neurite length of *Munc18-1* WT and HZ neurons. Mann–Whitney *U* test: n.s. = non-significant. **F**, The Tukey/scatter plot shows that the number of DCV exocytosis events normalized by the poolsize (indicated as release fraction) is reduced in *Munc18-1* HZ neurons during the first eight bursts of high-frequency train-stimulation. Mann–Whitney *U* test: *p* < 0.001.

a much higher number of APs to trigger exocytosis and fuse with a much longer delay after the start of stimulation (Zucker, 1973; Rosenmund et al., 1993; Murthy et al., 1997; Persoon et al., 2018). Additionally, while SV exocytosis is generally confined to specialized presynaptic release sites (active zones), DCVs exocytosis frequently occurs at non-synaptic locations (Südhof and Rizo, 2011; van de Bospoort et al., 2012; Persoon et al., 2018) and synaptic DCV exocytosis may be outside the active zone. It is puzzling that the only mechanistic difference for the final stages of either pathways is the critical requirement of RAB3A in DCV but not SV exocytosis (Schlüter et al., 2004, 2006; Persoon et al., 2018). This seems insufficient to explain the strikingly different properties of the two pathways.

Endogenous expression of *Munc18-2* and *Munc18-3* is insufficient to support neuronal viability, synaptic transmission or DCV exocytosis in *Munc18-1* null neurons (Fig. 1; Santos et al., 2017; Verhage et al., 2000). Overexpression of MUNC18-2 or MUNC18-3 in *Munc18-1* null neurons compensates for the

absence of MUNC18-1 and restores viability, but does not support synaptic transmission or DCV exocytosis (Fig. 2; He et al., 2017; Santos et al., 2017). Hence, MUNC18-1 is the only MUNC18 paralog capable of supporting neuropeptide and neurotransmitter release in mouse CNS neurons. Likewise, only one SM-protein (MUNC18-2) mediates secretion from several blood cell types (Côte et al., 2009; Hackmann et al., 2013; Gutierrez et al., 2018; Cardenas et al., 2019), and different MUNC18 paralogs support distinct phases of secretion in the pancreas and lung (Oh and Thurmond, 2009; Oh et al., 2012; Lam et al., 2013; Jaramillo et al., 2019). Conversely, overexpression of MUNC18-2 in *Munc18-1* null chromaffin cells partly rescues DCV exocytosis (Gulyás-Kovács et al., 2007). Hence, with few exceptions, SM-proteins have highly specialized roles in different forms of regulated secretion, with little or no redundancy among its paralogs. In contrast, the (unknown) function of MUNC18-1 in neuronal viability (Santos et al., 2017) as well as its role in regulating the actin cytoskeleton (Pons-Vizcarra et al., 2019), show ample redundancy among SM-proteins.

We previously showed synaptic assembly of the brain and cortical layering in the absence of synaptic transmission in *Munc18-1* null mice (Verhage et al., 2000). Our current data suggest that in *Munc18-1* null brains, secretion of neuropeptides, neurotrophic factors, and axon guidance molecules from DCVs may be defective as well, implying that synaptic assembly and cortical layering do not require both secretory pathways. However, we cannot exclude that other, MUNC18-1 independent, secretion pathways may play a role during early brain development. Furthermore, one study recently challenged the conclusion that MUNC18-1 is dis-

pensable for cortical layering of the brain, using more transient interference with MUNC18-1 expression in a small fraction of developing neurons (Hamada et al., 2017). Such a role in brain development may be supported by DCV exocytosis, e.g., by BDNF release (Schwartz et al., 1997; Borghesani et al., 2002; Medina et al., 2004; Zhou et al., 2007).

Neuropeptide/neurotrophin signaling is also associated with at least two other aspects of brain development. First, NPY and BDNF promote neural stem cell proliferation and differentiation during development (Hansel et al., 2001; Zhang et al., 2011; Chen et al., 2013). Second, BDNF signaling promotes layer-specific branching of callosal axons *in vivo* (Shimojo et al., 2015) and self-amplifying BDNF signaling underlies axonal differentiation and growth *in vitro* (Cheng et al., 2011). Therefore, it seems plausible that neuropeptides/neurotrophins are released during early brain development in *Munc18-1* null mice, potentially via constitutive secretion.




Figure 6. HZ inactivation of *Munc18-1* reduces exocytosis of BDNF-pHluorin-labeled DCVs. **A**, The histogram shows the average number of DCV exocytosis events for *Munc18-1* WT (black) and HZ (magenta) neurons infected with BDNF-pHluorin (sample size is indicated as *n/N*). The blue bars indicate the two stimulation paradigms (8 times 50 APs at 50 Hz). Error bars are SEM. **B**, Cumulative representation of the data in **A**. Error bars are SEM. **C**, The Tukey/scatter plot shows that the total number of DCV exocytosis events during the first train-stimulation is decreased in *Munc18-1* HZ neurons. Mann–Whitney *U* test: $*p < 0.05$. **D**, The Tukey/scatter plot shows the total number of DCV exocytosis events during the second train-stimulation for *Munc18-1* WT and HZ neurons. Mann–Whitney *U* test: n.s. = non-significant. **E**, The Tukey/scatter plot shows that the ratio of the number of exocytosis events between the second and first train-stimulation (potentiation) is higher in *Munc18-1* HZ

neurons. Mann–Whitney *U* test: $*p < 0.05$. **F**, Normalized cumulative representation of the data in **A**. Error bars are SEM. **G**, The Tukey/scatter plot shows the median delay of BDNF-pHluorin-labeled DCV exocytosis events relative to the start of each train-stimulation for *Munc18-1* WT and HZ neurons. The delay within each train-stimulation is similar between *Munc18-1* WT and HZ neurons. In both WT and HZ neurons, the median delay of exocytosis is decreased during the second train-stimulation compared with the first. Kruskal–Wallis with Dunn’s correction: $***p < 0.001$, n.s. = non-significant. **H**, The Tukey/scatter plot shows that the total pool of DCVs per cell, revealed by NH_4 application, is similar for *Munc18-1* WT and HZ neurons. Mann–Whitney *U* test: ns = non-significant. **I**, The Tukey/scatter plot shows that the number of DCV exocytosis events normalized by the total pool (indicated as release fraction) is decreased in *Munc18-1* HZ neurons during the first train-stimulation. Mann–Whitney *U* test: $*p < 0.05$. **J**, The Tukey/scatter plot shows the number of DCV exocytosis events normalized by the total pool (indicated as release fraction) for *Munc18-1* WT and HZ neurons during the second train-stimulation. Mann–Whitney *U* test: n.s. = non-significant.

BDNF-pHluorin and NPY-pHluorin label a largely overlapping population of DCVs (De Wit et al., 2009; Persoon et al., 2018), but NPY-pHluorin exocytosis events in WT neurons occurred 50% less frequently than BDNF-pHluorin events on the same stimulation (Figs. 4, 6). Numbers of NPY-pHluorin-labeled or BDNF-pHluorin-labeled DCVs were similar (Figs. 4, 6). NPY is inhibits synaptic transmission (Raposinho et al., 1999; Tschenett et al., 2003), while BDNF stimulates spontaneous and evoked synaptic transmission (Collin et al., 2001; Tartaglia et al., 2001; Tyler and Pozzo-Miller, 2001; Shinoda et al., 2014). Our data suggest that NPY and BDNF exert a similar effect on DCV exocytosis.

We observed a different effect size between two datasets obtained with NPY-pHluorin (Figs. 3, 4), possibly because of differences in culture conditions (supplements, coatings). However, meta-analysis on both data-sets shows clearly reduced DCV exocytosis on HZ *Munc18-1* inactivation (Fig. 5). To confirm this conclusion with an independent line of evidence, we used DCV exocytosis marker BDNF-pHluorin, and also observed reduced DCV exocytosis in *Munc18-1* HZ neurons (Fig. 6). Hence, HZ *Munc18-1* inactivation reduces DCV exocytosis almost proportionally, by 36–56% (Figs. 6, 4, respectively), while protein levels are 50% reduced (Verhage et al., 2000; Toonen et al., 2005, 2006b; Lee et al., 2019). In contrast, HZ *Munc18-1* inactivation barely affected chromaffin cell secretion, although docking was ~3-fold reduced (Toonen et al., 2006a), and hippocampal synapses from *Munc18-1* HZ mice had a normal first evoked response (Toonen et al., 2006b). This suggests that DCV exocytosis is generally more vulnerable to reduced MUNC18-1 protein levels than other regulated secretion pathways. However, specific synapses in the brains of *Munc18-1* HZ mice did show substantial impairments, a 40% reduction in synaptic transmission in synapses between neocortical neurons and striatal fast spiking interneurons (Miyamoto et al., 2019) and 45% in synapses between PV interneurons and pyramidal neurons (Chen et al., 2020).

Normal MUNC18-1 expression levels are especially required during the high initial rate of DCV exocytosis, which is ~5 times higher than in later phases (Fig. 3; Arora et al., 2017; Persoon et al., 2018, 2019; Hoogstraaten et al., 2020). In contrast, *Munc18-1* HZ chromaffin cells and synapses showed the largest effects during later phases of release (Toonen et al., 2006a,b; Miyamoto et al., 2019), albeit using different stimulation paradigms. It is tempting to speculate that the MUNC18-1-dependent rate-limiting step in the secretory pathway (probably docking/priming and setting up *trans*-SNARE-complexes) has already taken place before the onset of stimulation in chromaffin cells and synapses,

←

neurons. Mann–Whitney *U* test: $*p < 0.05$. **F**, Normalized cumulative representation of the data in **A**. Error bars are SEM. **G**, The Tukey/scatter plot shows the median delay of BDNF-pHluorin-labeled DCV exocytosis events relative to the start of each train-stimulation for *Munc18-1* WT and HZ neurons. The delay within each train-stimulation is similar between *Munc18-1* WT and HZ neurons. In both WT and HZ neurons, the median delay of exocytosis is decreased during the second train-stimulation compared with the first. Kruskal–Wallis with Dunn’s correction: $***p < 0.001$, n.s. = non-significant. **H**, The Tukey/scatter plot shows that the total pool of DCVs per cell, revealed by NH_4 application, is similar for *Munc18-1* WT and HZ neurons. Mann–Whitney *U* test: ns = non-significant. **I**, The Tukey/scatter plot shows that the number of DCV exocytosis events normalized by the total pool (indicated as release fraction) is decreased in *Munc18-1* HZ neurons during the first train-stimulation. Mann–Whitney *U* test: $*p < 0.05$. **J**, The Tukey/scatter plot shows the number of DCV exocytosis events normalized by the total pool (indicated as release fraction) for *Munc18-1* WT and HZ neurons during the second train-stimulation. Mann–Whitney *U* test: n.s. = non-significant.

while for neuronal DCVs this occurs after the onset. Such a scenario may help to explain why neuronal DCV exocytosis is so much slower than SV exocytosis and why the initial secretion response in synapses and chromaffin cells is hardly affected by reduced MUNC18-1 expression.

In dual train-stimulated neurons (two episodes of 8×50 APs), NPY-pHluorin and BDNF-pHluorin exocytosis events were accelerated at the onset of the second stimulation compared with the first (Figs. 4, 6). To our knowledge, such an acceleration of neuronal DCV exocytosis has not been reported before. *Munc18-1* HZ inactivation did not affect this acceleration (Figs. 4, 6). Hence, normal MUNC18-1 expression levels are not required for the acceleration of DCV exocytosis during a second train-stimulation. However, neurons with a reduced MUNC18-1 level, but not WT neurons, show potentiation of DCV exocytosis during the second train-stimulation (Figs. 4, 6). Potentiation of DCV exocytosis during dual stimulation has also been observed in (WT) *Drosophila* neuromuscular junctions, where ER-mediated calcium release elevates neuropeptide release via CaMKII during a second stimulation episode (Shakiryanova et al., 2007). However, mouse neuronal DCV exocytosis is normal in the absence of both α and β CaMKII (Moro et al., 2020), suggesting that a possible potentiation mechanism does not depend on CaMKII in mouse neurons.

This study shows that neuronal DCV exocytosis is particularly vulnerable to reduced MUNC18-1 expression levels. This finding may be relevant for *STXB1* syndrome, which is caused by mutations in the human *STXB1* gene (encoding for MUNC18-1) and characterized by developmental delay, intellectual disability, often epilepsy, motor abnormalities and sometimes also autistic traits (Saitsu et al., 2008; Stamberger et al., 2016; Abramov et al., 2020). Haploinsufficiency, because of impaired MUNC18-1/*STXB1* protein stability and consequently reduced cellular levels, is considered to explain the disease in most cases (Guiberson et al., 2018; Kovacevic et al., 2018; Verhage and Sørensen, 2020). *Munc18-1* HZ mice recapitulate the major hallmarks of *STXB1* syndrome (Kovacevic et al., 2018; Miyamoto et al., 2019; Chen et al., 2020). Impaired neuropeptide secretion may contribute, in addition to reduced synaptic transmission, to the behavioral and neurodevelopmental phenotypes in *Munc18-1* HZ mice and the pathogenesis of *STXB1* syndrome.

References

- Aalto MK, Ronne H, Keränen S (1993) Yeast syntaxins Sso1p and Sso2p belong to a family of related membrane proteins that function in vesicular transport. *EMBO J* 12:4095–4104.
- Abramov D, Guiberson NGL, Burré J (2020) *STXB1* encephalopathies: clinical spectrum, disease mechanisms, and therapeutic strategies. *J Neurochem* 157:165–178.
- André T, Classen J, Brenner P, Betts MJ, Dörr B, Kreye S, Zuidinga B, Meijer M, Russell RB, Verhage M, Söllner TH (2020) The interaction of Munc18-1 helix 11 and 12 with the central region of the VAMP2 SNARE motif is essential for SNARE templating and synaptic transmission. *eNeuro* 7:ENEURO.0278-20.2020.
- Arora S, Saarloos I, Kooistra R, van de Bospoort R, Verhage M, Toonen RF (2017) SNAP-25 gene family members differentially support secretory vesicle fusion. *J Cell Sci* 130:1877–1889.
- Bin NR, Jung CH, Piggott C, Sugita S (2013) Crucial role of the hydrophobic pocket region of Munc18 protein in mast cell degranulation. *Proc Natl Acad Sci USA* 110:4610–4615.
- Borghesani PR, Peyrin JM, Klein R, Rubin J, Carter AR, Schwartz PM, Luster A, Corfas G, Segal RA (2002) BDNF stimulates migration of cerebellar granule cells. *Development* 129:1435–1442.
- Burkhardt P, Hattendorf DA, Weis WI, Fasshauer D (2008) Munc18a controls SNARE assembly through its interaction with the syntaxin N-peptide. *EMBO J* 27:923–933.
- Cao P, Yang X, Südhof TC (2013) Complexin activates exocytosis of distinct secretory vesicles controlled by different synaptotagmins. *J Neurosci* 33:1714–1727.
- Cardenas EI, Gonzalez R, Breaux K, Da Q, Gutierrez BA, Ramos MA, Cardenas RA, Burns AR, Rumbaut RE, Adachi R (2019) Munc18-2, but not Munc18-1 or Munc18-3, regulates platelet exocytosis, hemostasis, and thrombosis. *J Biol Chem* 294:4784–4792.
- Chen BY, Wang X, Wang ZY, Wang YZ, Chen LW, Luo ZJ (2013) Brain-derived neurotrophic factor stimulates proliferation and differentiation of neural stem cells, possibly by triggering the Wnt/ β -catenin signaling pathway. *J Neurosci Res* 91:30–41.
- Chen W, Cai ZL, Chao ES, Chen H, Longley CM, Hao S, Chao HT, Kim JH, Messier JE, Zoghbi HY, Tang J, Swann JW, Xue M (2020) *Stxbp1*/Munc18-1 haploinsufficiency impairs inhibition and mediates key neurological features of *STXB1* encephalopathy. *Elife* 9:e48705.
- Cheng PL, Song AH, Wong YH, Wang S, Zhang X, Poo MM (2011) Self-amplifying autocrine actions of BDNF in axon development. *Proc Natl Acad Sci USA* 108:18430–18435.
- Cijsouw T, Weber JP, Broeke JH, Broek JAC, Schut D, Kroon T, Saarloos I, Verhage M, Toonen RF (2014) Munc18-1 redistributes in nerve terminals in an activity- and PKC-dependent manner. *J Cell Biol* 204:759–775.
- Collin C, Vicario-Abejon C, Rubio ME, Wenthold RJ, McKay RDG, Segal M (2001) Neurotrophins act at presynaptic terminals to activate synapses among cultured hippocampal neurons. *Eur J Neurosci* 13:1273–1282.
- Comeras LB, Herzog H, Tasan RO (2019) Neuropeptides at the crossroad of fear and hunger: a special focus on neuropeptide Y. *Ann NY Acad Sci* 1455:59–80.
- Côte M, Ménager MM, Burgess A, Mahlaoui N, Picard C, Schaffner C, Al-Manjomi F, Al-Harbi M, Alangari A, Le Deist F, Gennery AR, Prince N, Cariou A, Nitschke P, Blank U, El-Ghazali G, Ménasché G, Latour S, Fischer A, de Saint Basile G (2009) Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. *J Clin Invest* 119:3765–3773.
- Cropper EC, Jing J, Vilim FS, Weiss KR (2018) Peptide cotransmitters as dynamic, intrinsic modulators of network activity. *Front Neural Circuits* 12:1–7.
- de Wit H, Walter AM, Milosevic I, Gulyás-Kovács A, Riedel D, Sørensen JB, Verhage M (2009) Synaptotagmin-1 docks secretory vesicles to syntaxin-1/SNAP-25 receptor complexes. *Cell* 138:935–946.
- De Wit J, Toonen RF, Verhage M (2009) Matrix-dependent local retention of secretory vesicle cargo in cortical neurons. *J Neurosci* 29:23–37.
- Dulubova I, Khvotchev M, Liu S, Huryeva I, Südhof TC, Rizo J (2007) Munc18-1 binds directly to the neuronal SNARE complex. *Proc Natl Acad Sci USA* 104:2697–2702.
- Farina M, van de Bospoort R, He E, Persoon CM, van Weering JR, Broeke JH, Verhage M, Toonen RF (2015) CAPS-1 promotes fusion competence of stationary dense-core vesicles in presynaptic terminals of mammalian neurons. *Elife* 4:e05438.
- Granseth B, Odermatt B, Royle SJJ, Lagnado L (2006) Clathrin-mediated endocytosis is the dominant mechanism of vesicle retrieval at hippocampal synapses. *Neuron* 51:773–786.
- Guiberson NGL, Pineda A, Abramov D, Kharel P, Carnazza KE, Wragg RT, Dittman JS, Burré J (2018) Mechanism-based rescue of Munc18-1 dysfunction in varied encephalopathies by chemical chaperones. *Nat Commun* 9:3986.
- Gulyás-Kovács A, De Wit H, Milosevic I, Kochubey O, Toonen R, Klingauf J, Verhage M, Sørensen JB (2007) Munc18-1: sequential interactions with the fusion machinery stimulate vesicle docking and priming. *J Neurosci* 27:8676–8686.
- Gutierrez BA, Chavez MA, Rodarte AI, Ramos M, Dominguez A, Petrova Y, Davalos AJ, Costa RM, Elizondo R, Tuvim MJ, Dickey BF, Burns AR, Heidelberger R, Adachi R (2018) Munc18-2, but not Munc18-1 or Munc18-3, controls compound and single-vesicle regulated exocytosis in mast cells. *J Biol Chem* 293:7148–7159.
- Hackmann Y, Graham SC, Ehl S, Höning S, Lehmeberg K, Aricò M, Owen DJ, Griffiths GM (2013) Syntaxin binding mechanism and disease-causing mutations in Munc18-2. *Proc Natl Acad Sci USA* 110:E4482–E4491.

- Hamada N, Iwamoto I, Tabata H, Nagata KI (2017) MUNC18-1 gene abnormalities are involved in neurodevelopmental disorders through defective cortical architecture during brain development. *Acta Neuropathol Commun* 5:92.
- Hansel DE, Eipper BA, Ronnett GV (2001) Neuropeptide Y functions as a neuroproliferative factor. *Nature* 410:940–944.
- He E, Wierda K, Van Westen R, Broeke JH, Toonen RF, Cornelisse LN, Verhage M (2017) Munc13-1 and Munc18-1 together prevent NSF-dependent de-priming of synaptic vesicles. *Nat Commun* 8:15915.
- Heeroma JH, Roelandse M, Wierda K, Van Aerde KI, Toonen RFG, Hensbroek RA, Brussaard A, Matus A, Verhage M (2004) Trophic support delays but not prevent cell-intrinsic degeneration of neurons deficient for munc18-1. *Eur J Neurosci* 20:623–634.
- Hoogstraaten RI, Keimpema L, VanToonen RF, Verhage M (2020) Tetanus insensitive VAMP2 differentially restores synaptic and dense core vesicle fusion in tetanus neurotoxin treated neurons. *Sci Rep* 10:10913.
- Jahn R, Scheller RH (2006) SNAREs - engines for membrane fusion. *Nat Rev Mol Cell Biol* 7:631–643.
- Jaramillo AM, Piccotti L, Velasco WV, Delgado ASH, Azzegagh Z, Chung F, Nazeer U, Farooq J, Brenner J, Parker-Thornburg J, Scott BL, Evans CM, Adachi R, Burns AR, Kreda SM, Tuvim MJ, Dickey BF (2019) Different Munc18 proteins mediate baseline and stimulated airway mucin secretion. *JCI Insight* 4:e124815.
- Jiao J, He M, Port SA, Baker RW, Xu Y, Qu H, Xiong Y, Wang Y, Jin H, Eisemann TJ, Hughson FM, Zhang Y (2018) Munc18-1 catalyzes neuronal SNARE assembly by templating SNARE association. *Elife* 7:e41771.
- Kaesler PS, Regehr WG (2014) Molecular mechanisms for synchronous, asynchronous, and spontaneous neurotransmitter release. *Annu Rev Physiol* 76:333–363.
- Kaesler PS, Deng L, Wang Y, Dulubova I, Liu X, Rizo J, Südhof TC (2011) RIM proteins tether Ca²⁺ channels to presynaptic active zones via a direct PDZ-domain interaction. *Cell* 144:282–295.
- Kauppi M, Wohlfahrt G, Olkkonen VM (2002) Analysis of the Munc18b-syntaxin binding interface. Use of a mutant Munc18b to dissect the functions of syntaxins 2 and 3. *J Biol Chem* 277:43973–43979.
- Korteweg N, Maia AS, Thompson B, Roubos EW, Burbach JPH, Verhage M (2005) The role of Munc18-1 in docking and exocytosis of peptide hormone vesicles in the anterior pituitary. *Biol Cell* 97:445–455.
- Kovacevic J, Maroteaux G, Schut D, Loos M, Dubey M, Pitsch J, Rimmelink E, Koopmans B, Crowley J, Cornelisse LN, Sullivan PF, Schoch S, Toonen RF, Stiedl O, Verhage M (2018) Protein instability, haploinsufficiency, and cortical hyper-excitability underlie STXB1 encephalopathy. *Brain* 141:1350–1374.
- Lam PPL, Ohno M, Dolai S, He Y, Qin T, Liang T, Zhu D, Kang Y, Liu Y, Kauppi M, Xie L, Wan WCY, Bin NR, Sugita S, Olkkonen VM, Takahashi N, Kasai H, Gaisano HY (2013) Munc18b is a major mediator of insulin exocytosis in rat pancreatic b-cells. *Diabetes* 62:2416–2428.
- Lee Y, Iikim YG, Pyeon HJ, Ahn JC, Logan S, Orock A, Joo KM, Lórinz A, Deák F (2019) Dysregulation of the SNARE-binding protein Munc18-1 impairs BDNF secretion and synaptic neurotransmission: a novel interventional target to protect the aging brain. *Geroscience* 41:109–123.
- Medina DL, Sciarretta C, Calella AM, Von Bohlen Und Halbach O, Unsicker K, Minichiello L (2004) TrkB regulates neocortex formation through the Shc/PLCgamma-mediated control of neuronal migration. *EMBO J* 23:3803–3814.
- Meijer M, Dörr B, Lammert HC, Blithikioti C, Weering JR, Toonen RF, Söllner TH, Verhage M (2018) Tyrosine phosphorylation of Munc18-1 inhibits synaptic transmission by preventing SNARE assembly. *EMBO J* 37:300–320.
- Mennerick S, Que J, Benz A, Zorumski CF (1995) Passive and synaptic properties of hippocampal neurons grown in microcultures and in mass cultures. *J Neurophysiol* 73:320–332.
- Miranda M, Morici JF, Zanoni MB, Bekinschtein P (2019) Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. *Front Cell Neurosci* 13:363.
- Misura KM, Scheller RH, Weis WI (2000) Three-dimensional structure of the neuronal-Sec1-syntaxin 1a complex. *Nature* 404:355–362.
- Miyamoto H, Tatsukawa T, Shimohata A, Yamagata T, Suzuki T, Amano K, Mazaki E, Raveau M, Ogiwara I, Oba-Asaka A, Hensch TK, Itoharu S, Sakimura K, Kobayashi K, Kobayashi K, Yamakawa K (2019) Impaired cortico-striatal excitatory transmission triggers epilepsy. *Nat Commun* 10:1917.
- Moro A, Woerden GM, VanToonen RF, Verhage M (2020) CaMKII controls neuromodulation via neuropeptide gene expression and axonal targeting of neuropeptide vesicles. *PLoS Biol* 18:e3000826.
- Murthy VN, Sejnowski TJ, Stevens CF (1997) Heterogeneous release properties of visualized individual hippocampal synapses. *Neuron* 18:599–612.
- Novick P, Schekman R (1979) Secretion and cell-surface growth are blocked in a temperature-sensitive mutant of *Saccharomyces cerevisiae*. *Proc Natl Acad Sci USA* 76:1858–1862.
- Novick P, Field C, Schekman R (1980) Identification of 23 complementation groups required for post-translational events in the yeast secretory pathway. *Cell* 21:205–221.
- Novick P, Ferro S, Schekman R (1981) Order of events in the yeast secretory pathway. *Cell* 25:461–469.
- Oh E, Thurmond DC (2009) Munc18c depletion selectively impairs the sustained phase of insulin release. *Diabetes* 58:1165–1174.
- Oh E, Kalwat MA, Kim MJ, Verhage M, Thurmond DC (2012) Munc18-1 regulates first-phase insulin release by promoting granule docking to multiple syntaxin isoforms. *J Biol Chem* 287:25821–25833.
- Pariso D, Pfau M, Scheutzw A, Wild K, Mayer MP, Malsam J, Sinning I, Söllner TH (2014) An extended helical conformation in domain 3a of Munc18-1 provides a template for SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex assembly. *J Biol Chem* 289:9639–9650.
- Persoon CM, Moro A, Nassal JP, Farina M, Broeke JH, Arora S, Dominguez N, van Weering JR, Toonen RF, Verhage M (2018) Pool size estimations for dense-core vesicles in mammalian CNS neurons. *EMBO J* 37:e99672.
- Persoon CM, Hoogstraaten RI, Nassal JP, van Weering JRT, Kaesler PS, Toonen RF, Verhage M (2019) The RAB3-RIM pathway is essential for the release of neuromodulators. *Neuron* 104:1065–1080.e12.
- Pons-Vizcarra M, Kurps J, Tawfik B, Sørensen JB, van Weering JRT, Verhage M (2019) MUNC18-1 regulates submembrane F-actin network, independently of syntaxin1 targeting, via hydrophobicity in β -sheet 10. *J Cell Sci* 132:234674.
- Protopopov V, Govindan B, Novick P, Gerst JE (1993) Homologs of the synaptobrevin/VAMP family of synaptic vesicle proteins function on the late secretory pathway in *S. cerevisiae*. *Cell* 74:855–861.
- Raposinho PD, Broqua P, Pierroz DD, Hayward A, Dumont Y, Quirion R, Junien JL, Aubert ML (1999) Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype. *Endocrinology* 140:4046–4055.
- Rosenmund C, Clements JD, Westbrook GL (1993) Nonuniform probability of glutamate release at a hippocampal synapse. *Science* 262:754–757.
- Saitu H, Kato M, Mizuguchi T, Hamada K, Osaka H, Tohyama J, Urano K, Kumada S, Nishiyama K, Nishimura A, Okada I, Yoshimura Y, Hirai SI, Kumada T, Hayasaka K, Fukuda A, Ogata K, Matsumoto N (2008) De novo mutations in the gene encoding STXB1 (MUNC18-1) cause early infantile epileptic encephalopathy. *Nat Genet* 40:782–788.
- Santos TC, Wierda K, Broeke JH, Toonen RF, Verhage M (2017) Early Golgi abnormalities and neurodegeneration upon loss of presynaptic proteins Munc18-1, syntaxin-1, or SNAP-25. *J Neurosci* 37:4525–4539.
- Schlüter OM, Schmitz F, Jahn R, Rosenmund C, Südhof TC (2004) A complete genetic analysis of neuronal Rab3 function. *J Neurosci* 24:6629–6637.
- Schlüter OM, Basu J, Südhof TC, Rosenmund C (2006) Rab3 superprimed synaptic vesicles for release: implications for short-term synaptic plasticity. *J Neurosci* 26:1239–1246.
- Schmitz SK, Hjorth JJJ, Joemai RMS, Wijntjes R, Eijgenraam S, de Bruijn P, Georgiou C, de Jong APH, van Ooyen A, Verhage M, Cornelisse LN, Toonen RF, Veldkamp WJH, Veldkamp W (2011) Automated analysis of neuronal morphology, synapse number and synaptic recruitment. *J Neurosci Methods* 195:185–193.
- Schwartz PM, Borghesani PR, Levy RL, Pomeroy SL, Segal RA (1997) Abnormal cerebellar development and foliation in BDNF(-/-) mice reveals a role for neurotrophins in CNS patterning. *Neuron* 19:269–281.
- Shakiryanova D, Klose MK, Zhou Y, Gu T, Deitcher DL, Atwood HL, Hewes RS, Levitan ES (2007) Presynaptic ryanodine receptor-activated calmodulin kinase II increases vesicle mobility and potentiates neuropeptide release. *J Neurosci* 27:7799–7806.
- Shimojo M, Courchet J, Pieraut S, Torabi-Rander N, Sando R, Polleux F, Maximov A (2015) SNAREs controlling vesicular release of BDNF and development of callosal axons. *Cell Rep* 11:1054–1066.

- Shinoda Y, Ahmed S, Ramachandran B, Bharat V, Brockelt D, Altas B, Dean C (2014) BDNF enhances spontaneous and activity-dependent neurotransmitter release at excitatory terminals but not at inhibitory terminals in hippocampal neurons. *Front Synaptic Neurosci* 6:27.
- Sitarska E, Xu J, Park S, Liu X, Quade B, Stepien K, Sugita K, Brautigam CA, Sugita S, Rizo J (2017) Autoinhibition of munc18-1 modulates synaptobrevin binding and helps to enable munc13-dependent regulation of membrane fusion. *Elife* 6:e24278.
- Stamberger H, Nikanorova M, Willemsen MH, Accorsi P, Angriman M, Baier H, Benkel-Herrenbrueck I, Benoit V, Budetta M, Caliebe A, Cantalupo G, Capovilla G, Casara G, Courage C, Deprez M, Destrée A, Dilena R, Erasmus CE, Fannemel M, Fjær R, et al. (2016) A neurodevelopmental disorder including epilepsy. *Neurology* 86:954–962.
- Südhof TC (2013) Neurotransmitter release: the last millisecond in the life of a synaptic vesicle. *Neuron* 80:675–690.
- Südhof TC, Rothman JE (2009) Membrane fusion: grappling with SNARE and SM proteins. *Science* 323:474–477.
- Südhof TC, Rizo J (2011) Synaptic vesicle exocytosis. *Cold Spring Harb Perspect Biol* 3:a005637.
- Tamori Y, Kawanishi M, Niki T, Shinoda H, Araki S, Okazawa H, Kasuga M (1998) Inhibition of insulin-induced GLUT4 translocation by Munc18c through interaction with syntaxin4 in 3T3-L1 adipocytes. *J Biol Chem* 273:19740–19746.
- Tartaglia N, Du J, Tyler WJ, Neale E, Pozzo-Miller L, Lu B (2001) Protein synthesis-dependent and -independent regulation of hippocampal synapses by brain-derived neurotrophic factor. *J Biol Chem* 276:37585–37593.
- Thurmond DC, Ceresa BP, Okada S, Elmendorf JS, Coker K, Pessin JE (1998) Regulation of insulin-stimulated GLUT4 translocation by Munc18c in 3T3L1 adipocytes. *J Biol Chem* 273:33876–33883.
- Thurmond DC, Kanzaki M, Khan A, Pessin JE (2000) Munc18c function is required for insulin-stimulated plasma membrane fusion of GLUT4 and insulin-responsive amino peptidase storage vesicles. *Mol Cell Biol* 20:379–388.
- Toonen RF, Verhage M (2003) Vesicle trafficking: pleasure and pain from SM genes. *Trends Cell Biol* 13:177–186.
- Toonen RF, Verhage M (2007) Munc18-1 in secretion: lonely Munc joins SNARE team and takes control. *Trends Neurosci* 30:564–572.
- Toonen RF, de Vries KJ, Zalm R, Südhof TC, Verhage M (2005) Munc18-1 stabilizes syntaxin 1, but is not essential for syntaxin 1 targeting and SNARE complex formation. *J Neurochem* 93:1393–1400.
- Toonen RF, Kochubey O, de Wit H, Gulyas-Kovacs A, Konijnenburg B, Sørensen JB, Klingauf J, Verhage M (2006a) Dissecting docking and tethering of secretory vesicles at the target membrane. *EMBO J* 25:3725–3737.
- Toonen RF, Wierda K, Sons MS, de Wit H, Cornelisse LN, Brussaard A, Plomp JJ, Verhage M (2006b) Munc18-1 expression levels control synapse recovery by regulating readily releasable pool size. *Proc Natl Acad Sci USA* 103:18332–18337.
- Tschenett A, Singewald N, Carli M, Balducci C, Salchner P, Vezzani A, Herzog H, Sperk G (2003) Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. *Eur J Neurosci* 18:143–148.
- Tyler WJ, Pozzo-Miller LD (2001) BDNF enhances quantal neurotransmitter release and increases the number of docked vesicles at the active zones of hippocampal excitatory synapses. *J Neurosci* 21:4249–4258.
- van de Bospoort R, Farina M, Schmitz SK, de Jong A, de Wit H, Verhage M, Toonen RF (2012) Munc13 controls the location and efficiency of dense-core vesicle release in neurons. *J Cell Biol* 199:883–891.
- Verhage M, Sørensen JB (2020) SNAREopathies: diversity in mechanisms and symptoms. *Neuron* 107:22–37.
- Verhage M, Maia AS, Plomp JJ, Brussaard AB, Heeroma JH, Vermeer H, Toonen RF, Hammer RE, van den Berg TK, Missler M, Geuze HJ, Südhof TC (2000) Synaptic assembly of the brain in the absence of neurotransmitter secretion. *Science* 287:864–869.
- Voets T, Toonen RF, Brian EC, de Wit H, Moser T, Rettig J, Südhof TC, Neher E, Verhage M (2001) Munc18-1 promotes large dense-core vesicle docking. *Neuron* 31:581–592.
- Wang S, Li Y, Gong J, Ye S, Yang X, Zhang R, Ma C (2019) Munc18 and Munc13 serve as a functional template to orchestrate neuronal SNARE complex assembly. *Nat Commun* 10:69.
- Wierda KDB, Toonen RFG, de Wit H, Brussaard AB, Verhage M (2007) Interdependence of PKC-dependent and PKC-independent pathways for presynaptic plasticity. *Neuron* 54:275–290.
- Yue F, Cheng Y, Breschi A, Vierstra J, Wu W, Ryba T, Sandstrom R, Ma Z, Davis C, Pope BD, Shen Y, Pervouchine DD, Djebali S, Thurman RE, Kaul R, Rynes E, Kirilusha A, Marinov GK, Williams BA, Trout D, et al. (2014) A comparative encyclopedia of DNA elements in the mouse genome. *Nature* 515:355–364.
- Zeisel A, Muñoz-Manchado M, Codeluppi AB, Lönnerberg S, Manno P, La G, Jureus A, Marques S, Munguba H, He L, Betsholtz C, Rolny C, Castelo-Branco G, Hjerling-Leffler J, Linnarsson S (2015) Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. *Science* 347:1138–1142.
- Zhang Q, Liu G, Wu Y, Sha H, Zhang P, Jia J (2011) BDNF promotes EGF-induced proliferation and migration of human fetal neural stem/progenitor cells via the PI3K/Akt pathway. *Molecules* 16:10146–10156.
- Zhou P, Porcionatto M, Pilapil M, Chen Y, Choi Y, Tolias KF, Bikoff JB, Hong EJ, Greenberg ME, Segal RA (2007) Polarized signaling endosomes coordinate BDNF-induced chemotaxis of cerebellar precursors. *Neuron* 55:53–68.
- Zucker RS (1973) Changes in the statistics of transmitter release during facilitation. *J Physiol* 229:787–810.